Lyell Immunopharma, Inc. — Director's Dealing 2024

Jun 17, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2024-06-14

Reporting Person: Klausner Richard (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-14	Option (right to buy)	$2.36	A	130000	Acquired	2034-06-13	Common Stock (130000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2967834	Direct
Common Stock	685365	Indirect

Footnotes

F1: Consists of 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust and 245,515 shares held by The Olivia Klausner Delaware Trust. The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein. The JTC Trust Company (Delaware) Limited is the trustee of each of the trusts.

F2: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date.